Examples of where MIDD has been used include dasatinib for Ph+, CML-CP and Ph+ALL, naxitamab-gqgk in combination with GM-CSF for high-risk neuroblastoma in bone and bone marrow, pembrolizumab in a PD-L1+ advanced relapsed or refractory solid tumor or lymphoma and trametinib and trametinib + dabrafenib in cancer with V600 mutations. The gene discussed is CSF2; the disease is lymphoma.